ERBB2 and breast carcinoma: According to the FDA drug label [12] and indications approved by the NMPA, everolimus in combination with exemestane is prescribed for the treatment of postmenopausal patients with HR‐positive/HER2‐negative advanced breast cancer who have not responded to prior therapy with letrozole or anastrozole.